Last Updated: 01/12/2025

MalCommit – Understanding Sexual Commitment and Early Differentiation of Malaria Transmission Stages

Objectives

The project aims to understand the processes responsible for the differentiation of asexual malaria blood-stage parasites into sexual forms. The anticipated results may open up new avenues for the development of transmission-blocking drugs and vaccines.

Principal Investigators / Focal Persons

Till Voss

Rationale and Abstract

Malaria is a devastating infectious disease elicited by protozoan parasites of the genus Plasmodium. In 2012, malaria caused over 200 million clinical cases and close to 700’000 deaths, mostly among young children in sub-Saharan Africa. Human-to-human transmission of malaria parasites via Anopheles mosquitoes represents the biggest obstacle for efficient malaria control. Infection of the insect vector requires the obligate ingestion of mature sexual precursor forms called gametocytes via the blood meal. Gametocytes are constantly produced during human blood infection where asexually replicating parasites undergo unlimited vegetative growth. During each round of proliferation a small subset of parasites undergo an irreversible switch from vegetative growth to cell cycle exit and sexual differentiation. This provides a continuous source of mature gametocytes, which are the only forms capable of infecting the mosquito vector and are therefore essential for malaria transmission. The regulatory basis of this cell fate decision process has long remained one of the largest mysteries in the biology of malaria parasites. Recent seminal work now uncovered AP2-G, a key transcription factor essential for gametocyte commitment. The switch from asexual proliferation to gametocyte differentiation is controlled through an epigenetic mechanism that regulates the expression of AP2-G. In asexual parasites, the ap2-g locus is silenced by heterochromatin protein 1 (HP1), an evolutionary conserved regulator of heritable gene silencing. Conditional depletion of HP1 is sufficient to activate AP2-G expression and to cause an irreversible switch to sexual differentiation.

Date

Jul 2015 — May 2020

Total Project Funding

$2.14M

Funding Details
Country / Project Site(s)

Switzerland

SHARE
SHARE